相似文献
1
Resistance is futile: Targeting the inhibitory FcγRIIB (CD32B) to maximize immunotherapy.
Oncoimmunology. 2015 Aug 12;5(2):e1069939. doi: 10.1080/2162402X.2015.1069939. eCollection 2016 Feb.
2
Immunotherapy targeting inhibitory Fcγ receptor IIB (CD32b) in the mouse is limited by monoclonal antibody consumption and receptor internalization.
J Immunol. 2013 Oct 15;191(8):4130-40. doi: 10.4049/jimmunol.1301430. Epub 2013 Sep 11.
3
Development and characterisation of monoclonal antibodies specific for the murine inhibitory FcγRIIB (CD32B).
Eur J Immunol. 2012 Aug;42(8):2109-20. doi: 10.1002/eji.201142302. Epub 2012 Jul 4.
4
Regulation of Monoclonal Antibody Immunotherapy by FcγRIIB.
J Clin Immunol. 2016 May;36 Suppl 1:88-94. doi: 10.1007/s10875-016-0247-8. Epub 2016 Feb 27.
5
New revelations from an old receptor: Immunoregulatory functions of the inhibitory Fc gamma receptor, FcγRIIB (CD32B).
J Leukoc Biol. 2018 Feb 6. doi: 10.1002/JLB.2MIR0917-354R.
6
FcγRIIB as a key determinant of agonistic antibody efficacy.
Curr Top Microbiol Immunol. 2014;382:355-72. doi: 10.1007/978-3-319-07911-0_16.
7
Antagonistic human FcγRIIB (CD32B) antibodies have anti-tumor activity and overcome resistance to antibody therapy in vivo.
Cancer Cell. 2015 Apr 13;27(4):473-88. doi: 10.1016/j.ccell.2015.03.005.
8
Monoclonal antibodies capable of discriminating the human inhibitory Fcgamma-receptor IIB (CD32B) from the activating Fcgamma-receptor IIA (CD32A): biochemical, biological and functional characterization.
Immunology. 2007 Jul;121(3):392-404. doi: 10.1111/j.1365-2567.2007.02588.x. Epub 2007 Mar 26.
9
Targeting the Antibody Checkpoints to Enhance Cancer Immunotherapy-Focus on FcγRIIB.
Front Immunol. 2019 Mar 12;10:481. doi: 10.3389/fimmu.2019.00481. eCollection 2019.
10
CD44 antibody-mediated amelioration of murine immune thrombocytopenia (ITP): mouse background determines the effect of FcγRIIb genetic disruption.
Transfusion. 2015 Jun;55(6 Pt 2):1492-500. doi: 10.1111/trf.12957. Epub 2014 Dec 15.
引用本文的文献
1
An MHC-Related Gene's Signature Predicts Prognosis and Immune Microenvironment Infiltration in Glioblastoma.
Int J Mol Sci. 2025 May 12;26(10):4609. doi: 10.3390/ijms26104609.
2
The ETS-family transcription factor PU.1 is a critical regulator of the inhibitory Fcγ receptor IIB expression in humans.
J Immunol. 2025 Aug 1;214(8):1937-1950. doi: 10.1093/jimmun/vkaf109.
3
FcγRIIB (CD32B) antibodies enhance immune responses through activating FcγRs.
Clin Exp Immunol. 2025 Jan 21;219(1). doi: 10.1093/cei/uxaf015.
4
The Immunosuppressive Receptor CD32b Regulation of Macrophage Polarization and Its Implications in Tumor Progression.
Int J Mol Sci. 2024 Sep 9;25(17):9737. doi: 10.3390/ijms25179737.
5
FcγRIIB expressed on CD8 T cells limits responsiveness to PD-1 checkpoint inhibition in cancer.
Sci Transl Med. 2023 Aug 23;15(710):eadd1868. doi: 10.1126/scitranslmed.add1868.
6
FcγRIIB controls antibody-mediated target cell depletion by ITIM-independent mechanisms.
Cell Rep. 2022 Jul 19;40(3):111099. doi: 10.1016/j.celrep.2022.111099.
7
Targeting FcγRIIB by antagonistic antibody BI-1206 improves the efficacy of rituximab-based therapies in aggressive mantle cell lymphoma.
J Hematol Oncol. 2022 Apr 11;15(1):42. doi: 10.1186/s13045-022-01257-9.
8
FcγRIIB is a T cell checkpoint in antitumor immunity.
JCI Insight. 2021 Feb 22;6(4):135623. doi: 10.1172/jci.insight.135623.
9
Genome-wide discovery of somatic regulatory variants in diffuse large B-cell lymphoma.
Nat Commun. 2018 Oct 1;9(1):4001. doi: 10.1038/s41467-018-06354-3.
本文引用的文献
1
Antagonistic human FcγRIIB (CD32B) antibodies have anti-tumor activity and overcome resistance to antibody therapy in vivo.
Cancer Cell. 2015 Apr 13;27(4):473-88. doi: 10.1016/j.ccell.2015.03.005.
2
Antigenic modulation limits the effector cell mechanisms employed by type I anti-CD20 monoclonal antibodies.
Blood. 2015 Mar 19;125(12):1901-9. doi: 10.1182/blood-2014-07-588376. Epub 2015 Jan 28.
3
Expression of the inhibitory Fc gamma receptor IIB (FCGR2B, CD32B) on follicular lymphoma cells lowers the response rate to rituximab monotherapy (SAKK 35/98).
Br J Haematol. 2015 Jan;168(1):145-8. doi: 10.1111/bjh.13071. Epub 2014 Aug 21.
4
Sensitizing protective tumor microenvironments to antibody-mediated therapy.
Cell. 2014 Jan 30;156(3):590-602. doi: 10.1016/j.cell.2013.12.041.
5
Inhibitory FcγRIIb (CD32b) becomes activated by therapeutic mAb in both cis and trans and drives internalization according to antibody specificity.
Blood. 2014 Jan 30;123(5):669-77. doi: 10.1182/blood-2013-04-490821. Epub 2013 Nov 13.
6
Fcγ receptor IIb strongly regulates Fcγ receptor-facilitated T cell activation by dendritic cells.
J Immunol. 2012 Jul 1;189(1):92-101. doi: 10.4049/jimmunol.1103703. Epub 2012 May 30.
7
Fc gamma receptor IIb on target B cells promotes rituximab internalization and reduces clinical efficacy.
Blood. 2011 Sep 1;118(9):2530-40. doi: 10.1182/blood-2011-01-330357. Epub 2011 Jul 18.
8
Metastatic melanomas express inhibitory low affinity fc gamma receptor and escape humoral immunity.
Dermatol Res Pract. 2010;2010:657406. doi: 10.1155/2010/657406. Epub 2010 Jun 28.
9
Fcgamma receptors as regulators of immune responses.
Nat Rev Immunol. 2008 Jan;8(1):34-47. doi: 10.1038/nri2206.
10
Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets.
Nat Med. 2000 Apr;6(4):443-6. doi: 10.1038/74704.
Zotero 插件